Future of HIV-1 Therapeutics

Future of HIV-1 Therapeutics

Resistance Is Futile?

Torbett, Bruce; Goodsell, David S.; Richman, Douglas D.

Springer International Publishing AG

10/2016

254

Mole

Inglês

9783319374505

15 a 20 dias

HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented.
HIV Therapy Looking Towards the Future David Looney, Ariel Ma, and Scott Johns Computational challenges of structure-based approaches applied to HIV Stefano Forli and Arthur J. Olson Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 Mattia Mori, Lesia Kovalenko, Sebastien Lyonnais, Danny Antaki, Bruce E. Torbett, Maurizio Botta, Gilles Mirambeau, and Yves Mely HIV-1 integrase multimerization as a therapeutic target Lei Feng, Ross Larue, Jacques J. Kessl, and Mamuka Kvaratskhelia Targeting HIV transcription: The quest for a functional cure Guillaume Mousseau, Sonia Mediouni, and Susana T. Valente Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder Stuart F.J. Le Grice HIV-1 Gag: An Emerging Target for Antiretroviral Therapy Philip R. Tedbury and Eric O. Freed The Triple Threat of HIV-1 Protease Inhibitors Marc Potempa, Sook-Kyung Lee, Richard Wolfenden, and Ronald Swanstrom Illustrations of the HIV Life Cycle David S. Goodsell
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.